Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265–277 (2012).
Ye, B., Smerin, D., Gao, Q., Kang, C. & Xiong, X. High-throughput sequencing of the immune repertoire in oncology: applications for clinical diagnosis, monitoring, and immunotherapies. Cancer Lett. 416, 42–56 (2018).
Srivatsan, S. et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum. Vaccines Immunother. 10, 52–63 (2014).
Frey, A. B. & Monu, N. Signaling defects in anti‐tumor T cells. Immunol. Rev. 222, 192–205 (2008).
Jensen-Jarolim, E. & Singer, J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev. Vaccines 10, 1281–1289 (2011).
Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021).
Zhang, X., Cui, H., Zhang, W., Li, Z. & Gao, J. Engineered tumor cell-derived vaccines against cancer: the art of combating poison with poison. Bioact. Mater. 22, 491–517 (2023).
van Niel, G. et al. Challenges and directions in studying cell–cell communication by extracellular vesicles. Nat. Rev. Mol. Cell Biol. 23, 369–382 (2022).
Kumari, P. et al. Host extracellular vesicles confer cytosolic access to systemic LPS licensing non-canonical inflammasome sensing and pyroptosis. Nat. Cell Biol. 25, 1860–1872 (2023).
Bhatta, R. et al. Metabolic tagging of extracellular vesicles and development of enhanced extracellular vesicle based cancer vaccines. Nat. Commun. 14, 8047 (2023).
Wang, S. et al. Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Sci. Transl. Med. 13, eabb6981 (2021).
Nam, G. H. et al. Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy. Adv. Mater. 32, 2002440 (2020).
Li, S., Xu, J., Qian, J. & Gao, X. Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation. Biomater. Sci. 8, 6978–6991 (2020).
Santos, P. & Almeida, F. Exosome-based vaccines: history, current state, and clinical trials. Front. Immunol. 12, 711565 (2021).
Ahmadi, M., Abbasi, R. & Rezaie, J. Tumor immune escape: extracellular vesicles roles and therapeutics application. Cell Commun. Signal. 22, 9 (2024).
Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386 (2018).
Yu, P. et al. Pyroptosis: mechanisms and diseases. Signal Transduct. Target. Ther. 6, 128 (2021).
Frank, D. & Vince, J. E. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 26, 99–114 (2019).
Faria, S. S. et al. NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. J. Biomed. Sci. 28, 26 (2021).
Li, Z. T. et al. Enhancing gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response. Nat. Commun. 13, 6321 (2022).
Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020).
Horrevorts, S. K. et al. Glycan-modified apoptotic melanoma-derived extracellular vesicles as antigen source for anti-tumor vaccination. Cancers 11, 1266 (2019).
Schnurr, M. et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γδ T cells. Cancer Res. 62, 2347–2352 (2002).
Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015).
Wang, G. et al. Tumour extracellular vesicles and particles induce liver metabolic dysfunction. Nature 618, 374–382 (2023).
Wang, Y. L. et al. Delivering antisense oligonucleotides across the blood-brain barrier by tumor cell-derived small apoptotic bodies. Adv. Sci. 8, 2004929 (2021).
Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860–875 (2012).
Chen, Y. L. et al. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation. Cancer Lett. 425, 152–163 (2018).
Mossoba, M. E. et al. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol. Ther. 16, 607–617 (2008).
Toldo, S. & Abbate, A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat. Rev. Cardiol. 21, 219–237 (2024).
Zamani, P., Oskuee, R. K., Atkin, S. L., Navashenaq, J. G. & Sahebkar, A. MicroRNAs as important regulators of the NLRP3 inflammasome. Prog. Biophys. Mol. Bio. 150, 50–61 (2020).
Ding, S., Liu, D., Wang, L., Wang, G. & Zhu, Y. Inhibiting microRNA-29a protects myocardial ischemia-reperfusion injury by targeting SIRT1 and suppressing oxidative stress and NLRP3-mediated pyroptosis pathway. J. Pharmacol. Exp. Ther. 372, 128–135 (2020).
Wang, Z., Sun, L., Jia, K., Wang, H. & Wang, X. miR-9-5p modulates the progression of Parkinson’s disease by targeting SIRT1. Neurosci. Lett. 701, 226–233 (2019).
Bai, D. et al. ALDOA maintains NLRP3 inflammasome activation by controlling AMPK activation. Autophagy 18, 1673–1693 (2022).
Karki, R. et al. NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer. Nature 540, 583–587 (2016).
Sharma, B. R. & Kanneganti, T. D. NLRP3 inflammasome in cancer and metabolic diseases. Nat. Immunol. 22, 550–559 (2021).
Zhang, X. et al. Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy. Nat. Commun. 14, 5653 (2023).
Chang, B. A., Cross, J. L., Najar, H. M. & Dutz, J. P. Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 27, 5791–5799 (2009).
Rodell, C. B. et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578–588 (2018).
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489–496 (2017).
Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168–182 (2018).
Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).
Wang, T. et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat. Commun. 9, 1532 (2018).
Wright, S. S. et al. Transplantation of gasdermin pores by extracellular vesicles propagates pyroptosis to bystander cells. Cell 188, P280-291.E17 (2024).
Bergsbaken, T., Fink, S. L. & Cookson, B. T. Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7, 99–109 (2009).
Ruhl, S. et al. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science 362, 956–960 (2018).
Vietri, M., Radulovic, M. & Stenmark, H. The many functions of ESCRTs. Nat. Rev. Mol. Cell Biol. 21, 25–42 (2020).
Baxter, A. A. et al. Analysis of extracellular vesicles generated from monocytes under conditions of lytic cell death. Sci. Rep. 9, 7538 (2019).
Zhang, Y. et al. Inflammasome-derived exosomes activate NF-κB signaling in macrophages. J. Proteome Res. 16, 170–178 (2017).
